Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of YDYNWY (SEQ ID NO: 1), YDYNLY (SEQ ID NO: 2), FDYNFY (SEQ ID NO: 3), FDYNLY (SEQ ID NO: 4), FDYNWY (SEQ ID NO: 5), YDWNLY (SEQ ID NO: 6), YDWHLY (SEQ ID NO: 7), and WDYNLY (SEQ ID NO: 8), extracted from organisms such as aquatic organisms and moss or any other sequence described herein, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.

The present invention relates to the field of antimicrobial agents active against Staphylococcus aureus bacteria. In particular, the present invention relates to polypeptides comprising the CHAP domain of LysK endolysin, the M23 endopeptidase domain of lysostaphin, the cell wall binding domain (CBD) of ALE-1, and a further peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a hydrophobic peptide, a sushi peptide and a defensin. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells, compositions and devices. Finally, the present invention relates to applications of the inventive polypeptides, in particular in the pharmaceutical field.

The invention relates to a device that is to be implanted in vivo and includes a stent (46) surrounded, at least partially, by at least one flexible conductive film (54, 56) containing chains of a linear polymer, each of which has carbon nanotubes connected thereto via pi-pi interactions. Said film is functionalized by enzymatic grafting so as to form an electrochemical bioreactor element.

According to this invention, the following are provided: a pharmaceutical composition for treating and/or preventing esophageal stenosis, comprising an HGF protein as an active ingredient (wherein the HGF protein may be a polypeptide that is any one of the following: (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2; (b) a polypeptide comprising an amino acid sequence shown in SEQ ID NO: 2 in which one to several amino acids are deleted, substituted, or added; or (c) a polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 2; and a stent comprising the pharmaceutical composition.

Disclosed is a medical device constructed and arranged for contact with a flow of blood or other bodily fluid of a patient and including an attached binding agent or a roughened surface that binds to pathogenic cells targeted for elimination from the blood or other bodily fluid. Also disclosed are methods for making and using the device.

Materials and methods for preventing gastrointestinal obstruction are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. The peptide may undergo self-organization under physiological conditions and/or in the presence of a cation.

3D printing of biopolymer-based inks provides for manufacturing a broad range of products with desirable properties. A print nozzle may be charged to form a cone-shaped ink droplet to result in increased resolution, more reliable contact with irregular surfaces, and a mechanism to control contacting the ink to the print surface.

A bio-ink composition comprises a plurality of bio-block, in which the bio-blocks can serve as basic building blocks in cell-based bioprinting. The bio-blocks, pharmaceutical compositions comprising the bio-blocks, methods of preparing artificial tissues, tissue progenitors, or multi-dimensional constructs, and methods of preparing the bio-blocks are also provided. The bio-blocks, and the multi-dimensional constructs, artificial tissues, and tissue progenitors comprising the bio-blocks or prepared by the methods described herein are useful for tissue engineering, in vitro research, stem cell differentiation, in vivo research, drug screening, drug discovery, tissue regeneration, and regenerative medicine.

The present invention concerns a process for the production of implants with an ultrahydrophilic surface as well as the implants produced in that way and also processes for the production of loaded, so-called bioactive implant surfaces of metallic or ceramic materials, which are used for implants such as artificial bones, joints, dental implants or also very small implants, for example what are referred to as stents, as well as implants which are further produced in accordance with the processes and which as so-called “delivery devices” allow controlled liberation, for example by way of dissociation, of the bioactive molecules from the implant materials.

The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.